Innovative Industrial Properties, Inc. announced that it entered into an amendment of the lease with PharmaCann Inc. in Hamptonburgh, New York, making available $45.0 million in funding for the development of a new 98,000-square-foot industrial building for cultivation and significant enhancements in production capacity and additional upgrades at the existing 127,000-square-foot facility. The lease amendment also adjusted the base rent under the lease to take into account the additional available funding for the development and qualifying improvements to the existing facilities. Assuming full payment of the additional funding, IIP's total investment in the 225,000-square-foot property will be $108.5 million (approximately $482 per square foot).

IIP originally acquired the New York property situated on approximately 42 acres of land for $30.0 million (approximately $236 per square foot) and entered into a long-term lease with PharmaCann in 2016, for a newly-constructed, 127,000-square-foot cannabis cultivation and processing facility, comprised of a 26,000-square-foot “headhouse” for processing and two 50,500-square-foot greenhouse cultivation buildings. The transaction was structured as a sale-leaseback, with the $30.0 million total investment based on PharmaCann's cost to acquire the land and develop the 127,000-square-foot property, which included the HVAC, electrical, plumbing and other building systems infrastructure necessary to support regulated cannabis cultivation and processing. In late 2020 and early 2021, IIP committed an additional $33.5 million, of which approximately $15.2 million has been disbursed to date for verified costs for specific infrastructure enhancements to the existing cultivation buildings and headhouse.

Those enhancements included the addition of two trim and dry rooms, the build out of the balance of one of the greenhouse buildings for additional cultivation space and additional upgrades to the other greenhouse building. After additional review of proposed expansion plans, PharmaCann determined to move forward with the construction of an industrial cultivation building as described below, in lieu of the previously planned 40,000-square-foot additional greenhouse facility. IIP's $45.0 million additional capital commitment, along with the remaining unfunded proceeds from the prior allowance, is expected to be utilized for the ground-up development of an approximately 98,000-square-foot, three level indoor cultivation facility, including a subterranean level to house specialized mechanical and electrical equipment for cultivation and a penthouse level for additional cultivation support.

Eligible direct costs for the project subject to reimbursement by IIP pursuant to the lease and associated development agreement for the project include site planning and preparation, base building construction and the enhanced HVAC, electrical, mechanical, fertigation and other building systems required for indoor cannabis cultivation. PharmaCann is also expected to complete additional renovations for the existing facility, including further infrastructure upgrades in the greenhouses and process optimization renovations in the headhouse, the costs of which will be eligible for reimbursement from IIP's capital commitment. In addition to this facility in New York, IIP owns and leases to PharmaCann five regulated cannabis dispensaries and five cultivation and processing facilities in Colorado, Illinois, Massachusetts, Michigan, Ohio and Pennsylvania, comprising a total of approximately 688,000 square feet (including expected square footage under development or redevelopment).

Assuming full reimbursement of funding for development and qualifying improvements under the leases, IIP's total investment in properties leased to PharmaCann is expected to be approximately $306.2 million. PharmaCann is IIP's largest tenant partner in terms of capital investment (including commitments to fund future qualifying improvements and development) and annualized base rents. As the pioneering real estate investment trust (REIT) for the regulated cannabis industry, IIP partners with experienced, regulated cannabis operators and serves as a source of capital by acquiring and leasing back their real estate assets, in addition to offering other creative real estate-based capital solutions.

PharmaCann and LivWell Enlightened Health, another tenant partner of IIP and one of the longest tenured cannabis operators in the industry, announced the completion of their merger in late February of this year. Together, the combined company's operational footprint consists of more than 50 dispensaries and ten cannabis production facilities across eight states. According to BDS Analytics, regulated cannabis sales in New York are expected to ramp from a projected $200 million in 2022 to $2.7 billion by 2026, a significant driver of overall U.S. regulated cannabis markets growth in coming years.

PharmaCann is one of ten vertically-integrated medical cannabis license holders, each of which is permitted to operate up to eight dispensaries, in addition to its cultivation and processing facility. The Marijuana Regulation and Taxation Act was signed into law on March 31, 2021, legalizing adult-use cannabis, with first sales of adult-use cannabis sales in New York potentially later this year.